PTC Therapeutics, Inc.
PTCTNASDAQHealthcare● Active
$70.31
$-0.66(-0.94%)
Market Cap$5.8B
P/E Ratio—
52W High$87.5
52W Low$43.175
PTC Therapeutics, Inc. (PTCT) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · PTCT · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.73B | $0.81B | $0.94B | $0.70B | $0.54B |
| Cost of Revenue | $0.07B | $0.06B | $0.07B | $0.04B | $0.03B |
| Gross Profit | $1.66B | $0.75B | $0.87B | $0.65B | $0.51B |
| Gross Margin %(computed) | 95.85% | 92.89% | 93.02% | 93.61% | 94.00% |
| Operating Expenses | |||||
| R&D Expenses | $0.46B | $0.53B | $0.67B | $0.65B | $0.54B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.80B | $1.05B | $1.31B | $1.10B | $0.88B |
| Operating Income | $0.86B | ($0.30B) | ($0.44B) | ($0.45B) | ($0.37B) |
| Operating Margin %(computed) | 49.49% | -37.50% | -46.86% | -64.03% | -69.52% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.15B | $0.17B | $0.13B | $0.09B | $0.09B |
| Income Before Tax | $0.70B | ($0.36B) | ($0.70B) | ($0.59B) | ($0.52B) |
| Income Tax Expense | $0.01B | $0.00B | ($0.07B) | ($0.03B) | $0.01B |
| Net Income | $0.68B | ($0.36B) | ($0.63B) | ($0.56B) | ($0.52B) |
| Net Margin %(computed) | 39.44% | -45.03% | -66.81% | -80.00% | -97.27% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $8.58 | $-4.73 | $-8.37 | $-7.79 | $-7.43 |
| Wtd Avg Shares | 0.08B | 0.08B | 0.07B | 0.07B | 0.07B |
| EBITDA | $0.89B | ($0.12B) | ($0.33B) | ($0.37B) | ($0.37B) |
| EBITDA Margin %(computed) | 51.29% | -14.93% | -35.22% | -52.63% | -68.36% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more PTC Therapeutics, Inc. data
About PTC Therapeutics, Inc. (PTCT) Income Statement
PTC Therapeutics, Inc. (PTCT) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, PTCT reported revenue of $1.73B, gross profit of $1.66B (gross margin 95.85%), and net income of $0.68B — a net profit margin of 39.44%.
Frequently asked questions
PTCT · 4 questionsPTC Therapeutics, Inc. (PTCT) reported revenue of $1.73B for 2025, up 114.5% year-over-year.
PTCT revenuePTCT salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08